Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811935 · ClinicalTrials.gov registry record
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
A clinical trial of PANS and PANDAS, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 30
- Enrollment target
- 2
- Study locations
NCT06811935: Recruiting study of PANS and PANDAS, sponsored by University of Wisconsin, Madison.
NCT06811935 is a study of PANS and PANDAS that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06811935, a study of PANS and PANDAS, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, course and outcome. The investigators aim to demonstrate they can recruit and retain 85% of children who are eligible for this study. Eligible children are those who fit criteria for PANS and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS). Each child will be followed for one year.
Primary Outcome
To demonstrate that the methods of recruitment are effective, the aim is to enroll 85 percent of children with PANS/PANDAS who meet preliminary eligibility criteria for the study.
Study Locations (2)
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Wisconsin
- UW School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2027-12 |
What NCT06811935 shows while recruiting
NCT06811935 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 2 conditions, with PANS appearing as the primary indexed condition, and to 0 interventions.
NCT06811935 reports a single indexed study location in New Hampshire, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06811935 about?
NCT06811935 is a clinical study titled "PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study". The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regar...
What is the current status of trial NCT06811935?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-02-17. Estimated completion is 2027-12.
What conditions does trial NCT06811935 study?
This clinical trial studies the following conditions: PANS, PANDAS.
Who is sponsoring clinical trial NCT06811935?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811935 being conducted?
This trial has 2 study locations across New Hampshire, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PANS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI